Last Price
21.27
Today's Change
+0.65 (3.15%)
Day's Change
20.76 - 21.56
Trading Volume
364,538
Market Cap
2 Billion
Shares Outstanding
127 Million
Avg Volume
421,424
Avg Price (50 Days)
20.03
Avg Price (200 Days)
18.75
PE Ratio
17.73
EPS
1.20
Earnings Announcement
29-Jul-2024
Previous Close
20.62
Open
20.84
Day's Range
20.76 - 21.56
Year Range
10.02 - 25.95
Trading Volume
364,538
1 Day Change
3.15%
5 Day Change
6.99%
1 Month Change
-7.96%
3 Month Change
0.24%
6 Month Change
-15.29%
Ytd Change
-14.30%
1 Year Change
73.63%
3 Year Change
1263.46%
5 Year Change
1749.57%
10 Year Change
1181.33%
Max Change
272.50%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.